Sufugolix

308831-61-0

C36H31F2N5O4S

DMSO : 1.25 mg/mL (1.87 mM; Need ultrasonic)

Others

Sufugolix (TAK-013) is a highly potent and orally available luteinizing hormone-releasing hormone (LHRH) receptor antagonist with an IC₅₀ of 0.1 nM. IC50 & Target: IC50: 0.1 nM (human LHRH), 0.6 nM (monkey LHRH)^[1] In Vitro: Sufugolix exhibits more than 3- and 2000-fold selectivity for the human receptor over the monkey and rat receptors, respectively. Sufugolix effectively antagonizes LHRH function on CHO cells expressing the human (IC₅₀=0.1 nM) and monkey (IC₅₀=0.6 nM) receptors. During the conformational analysis of sufugolix, using high-temperature molecular dynamics calculation, it is observed that the cis conformer of the methoxyurea is more populated than the trans conformer ^[1]. In Vivo: Oral administration of sufugolix causes almost complete suppression of the plasma LH levels in castrated male cynomolgus monkeys at a 30 mg/kg dose with sufficient duration of action (more than 24 h). The maximum plasma concentrations of sufugolix are 0.34 uM (reached 6 h after administration) and 0.18 uM (reached 4 h after administration) at 30 and 10 mg/kg doses, respectively^[1].